Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Liquid Biopsy Can Rule Out Early-Stage Lung Cancer

By LabMedica International staff writers
Posted on 05 Apr 2018
Lung nodules are a diagnostic challenge with an estimated yearly incidence of 1.6 million in the USA. More...
The majority of these patients have benign lung nodules; however, there are significant costs, morbidity and mortality associated with the invasive biopsies needed to determine which nodules are cancerous.

It has been found that of these pulmonary nodules detected each year more than 90% of those smaller than two centimeters (around 3/4 inch) in diameter are benign, and current detection methods include positron-emission tomography (PET) scans, bronchoscopy, needle biopsy, and surgery. A new study has confirmed the accuracy of a liquid biopsy that can help rule out early-stage lung cancer.

A large team of medical scientists working with those at the Medical University of South Carolina, Charleston, SC, USA) carried out a prospective multicenter observational trial of 685 patients with 8-30 mm lung nodules at 33 sites in the USA and Canada. Multiple reaction monitoring mass spectrometry measured the relative abundance of two plasma proteins, galectin-3 binding protein (LG3BP) and scavenger receptor cysteine-rich type 1 (C163A). Results were integrated with a clinical risk prediction model to identify likely benign nodules. Sensitivity, specificity and negative predictive value were calculated.

The liquid biopsy used in the study was the Xpresys Lung 2 ('XL2') a second-generation diagnostic test Integrated Diagnostic (Seattle, WA, USA). A subgroup of 178 patients had a 16% prevalence of lung cancer. The integrated classifier demonstrated a sensitivity of 97% a specificity of 44% and a negative predictive value (NPV) of 98% in distinguishing benign from malignant nodules. The classifier performed better than positron emission tomography (PET), validated lung nodule risk models, and physician cancer probability estimates. If the integrated classifier results were used to direct care, 40% fewer procedures would be performed on benign nodules while 3% of malignant nodules would be misclassified.

Albert Luderer, PhD, president of Integrated Diagnostics, said, “Physicians can often detect whether a patient is at high risk for cancer, but have difficulty determining when a small lung nodule is benign. Patients determined by traditional means to be at low risk are often put into a “watchful waiting” category to be re-tested over time. The XL2 test might help patients with low-to-moderate risk of cancer to avoid unnecessary invasive procedures.” The study was published on March 1, 2018, in the journal Chest.

Related Links:
Medical University of South Carolina
Integrated Diagnostic


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.